Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2022 | Combining immunotherapy and chemotherapy in rectal cancer

Ali Shamseddine • 12 Jan 2022
ASCO GI 2022
Colon Cancer Gastrointestinal Cancer

Ali Shamseddine, MD, American University of Beirut, Beirut, Lebanon, explains how there are many Phase II trials investigating the use of immunotherapy with chemotherapy in patients with rectal cancer but there is currently no method of selection for patients who will benefit from this combination. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022

More from Ali Shamseddine

2:15
Averectal: short-course radiation plus chemotherapy in addition to chemo-IO, followed by surgery
Ali Shamseddine • 12 Jan 2022
3:56
The use of the immunoscore in predicting the outcome of neoadjuvant chemotherapy in GI cancer
Ali Shamseddine • 12 Jan 2022
3:51
Averectal: neoadjuvant short-course RT followed by chemo + avelumab in rectal adenocarcinoma
Ali Shamseddine • 22 Jun 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals